Show simple item record

dc.contributor.authorShahzad, Yasser
dc.contributor.authorGerber, Minja
dc.contributor.authorDu Plessis, Jeanetta
dc.contributor.authorKhan, Ikram U.
dc.contributor.authorHussain, Talib
dc.identifier.citationShahzad, Y. et al. 2014. Bioactive albumin-based carriers for tumour chemotherapy. Current cancer drug targets, 14(8):752-763. []en_US
dc.identifier.issn1873-5576 (Online)
dc.description.abstractProteins are posed as the natural counterpart of the synthetic polymers for the development of drug delivery systems and few of them, have been regarded safe for drug delivery purposes by the United States Food and Drug Administration (FDA). Serum albumin is the most abundant protein in human blood. Interest in the exploration of pharmaceutical applications of albumin-based drug delivery carriers, especially for the delivery of chemotherapeutic agents, has increased in recent years. Albumin has several advantages over synthetic polymers, as it is biocompatible, biodegradable, has low cytotoxicity and has an excellent binding capacity with various drugs. Micro- and nano-carriers not only protect active pharmaceutical ingredients against degradation, but also offer a prolonged release of drugs in a controlled fashion. Since existing tumour chemotherapeutic agents neither target tumour cells, nor are they specific to tumour cells, a slow release of drugs from carriers would be beneficial in targeting carcinogenic cells intracellularly. This article aims at providing an overview of pharmaceutical applications of albumin as a drug delivery carrier in tumour chemotherapyen_US
dc.publisherBentham Scienceen_US
dc.subjectdrug deliveryen_US
dc.titleBioactive albumin-based carriers for tumour chemotherapyen_US
dc.contributor.researchID11329025 - Gerber, Minja
dc.contributor.researchID10065318 - Du Plessis, Jeanetta

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record